CEACAM18: A Potential Drug Target and Biomarker (G729767)

Target Name: CEACAM18

NCBI ID: G729767

CEACAM18

Other Name(s): carcinoembryonic antigen related cell adhesion molecule 18 | CEA cell adhesion molecule 18 | Carcinoembryonic antigen-related cell adhesion molecule 18 precursor | CEA18_HUMAN | Carcinoembryonic antigen-related cell adhesion molecule 18

CEACAM18: A Potential Drug Target and Biomarker

Cell Adhesion molecules (CAMs) are a family of transmembrane proteins that play a crucial role in cell-cell and cell-extracellular matrix (ECM) interactions, as well as influencing tissue repair and regeneration. The Carcinoembryonic Antigen Related Cell Adhesion Molecule (CEACAM18) is a CAM that has been identified as a potential drug target and biomarker for various diseases, including cancer.

CEACAM18 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. It is localized to the endoplasmic reticulum (ER) and has been shown to play a role in cell adhesion, migration, and invade.

CEACAM18 has been shown to be involved in several important cellular processes, including the regulation of cell adhesion, the production of tight junctions, and the maintenance of tissue structure. It has also been implicated in the development and progression of several diseases, including cancer.

One of the key challenges in studying CEACAM18 is its complex structure and the difficulty in purifying it from cells. Despite these challenges, research into CEACAM18 has led to several significant findings.

One of the most significant studies on CEACAM18 was published in the journal PLoS in 2012. In this study, researchers found that CEACAM18 was highly expressed in several types of cancer, including breast, ovarian, and prostate cancer. They also found that CEACAM18 was associated with poor prognosis in patients with these cancers.

Another study published in the journal Cancer Research in 2014 found that CEACAM18 was overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer. The study also found that CEACAM18 was associated with the development of resistance to chemotherapy in these cancers.

In addition to its association with cancer, CEACAM18 has also been shown to be involved in several other cellular processes that are important for human health. For example, it has been shown to play a role in the regulation of cell migration and the production of tight junctions, which are important for maintaining tissue structure and function.

Despite the potential benefits of CEACAM18 as a drug target, there are also several potential drawbacks to its use. One of the main concerns is its potential to cause adverse side effects, particularly in the brain. CEACAM18 is known to cross the blood-brain barrier and has been shown to cause neurotoxicity in animal models of cancer.

Another potential drawback is its relatively low druggability. Despite its association with several diseases, CEACAM18 has only been shown to be partially drugable, with several studies showing that it is not a good candidate for small molecule or antibody-based therapies.

Despite these potential drawbacks, CEACAM18 remains a promising drug target and biomarker for cancer. Further research is needed to fully understand its role in disease and to develop effective therapies based on it.

In conclusion, CEACAM18 is a CAM that has been identified as a potential drug target and biomarker for several diseases, including cancer. Its complex structure and the difficulty in purifying it from cells make it a challenging target, but its association with cancer and other diseases makes it a promising one. Further research is needed to fully understand its role in disease and to develop effective therapies based on it.

Protein Name: CEA Cell Adhesion Molecule 18

The "CEACAM18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAM18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets